Amman - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable), the multinational pharmaceutical group, is providing an update on current trading.

Siggi Olafsson, Hikma’s CEO, said: “I am pleased to reiterate our full year guidance for the Group in 2019. We continue to execute against our strategic priorities and all three of our businesses continue to deliver good organic growth and profitability in line with our expectations. We are benefitting from our broad and differentiated product portfolios, strong commercial capabilities and tight cost control. We are successfully launching new products while making strategic investments in R&D and partnerships to drive sustainable long-term growth.”

The global Injectables business continues to perform well. In the US, good demand for the large and resilient portfolio, including recent product launches, is more than offsetting increased competition on certain products and the gradual decline in revenue from shortages of pain management products, as expected. Businesses in Europe and MENA are also performing well. Global Injectables revenue continues to be expected in the range of $870 million to $900 million for the full year in 2019 and for core operating margin to be in the range of 36% to 38%. 

The Generics business is delivering good revenue growth and a strong improvement in profitability. This reflects strong demand for Hikma’s differentiated portfolio, continued operational improvements and a focus on cost reduction. For the full year, Generics revenue is expected to be closer to the top end of the guidance range of $690 million to $720 million and core operating margin continues to be in the range of 16% to 18%. 

The Branded business is performing well. Strong growth in most markets, including Egypt and Saudi Arabia, is more than offsetting lower sales in Algeria, where market conditions continue to be challenging. Hikma continues to expect Branded revenue growth in constant currency to be in the mid-single digits for the full year in 2019.

Results for the year ended 31 December 2019 will be announced on 27 February 2020.

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.